STOCK TITAN

[Form 4] Snowflake Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

MetLife, Inc. (MET) filed a Form 144 announcing a proposed sale of 547 shares of common stock through Barclays Capital on 20 June 2025. The aggregate market value of the proposed sale is $42,966.85, compared with 671,297,826 shares currently outstanding, representing roughly 0.00008 % of shares outstanding.

The filing lists prior sales over the past three months by various MetLife-related accounts totaling 686 shares and gross proceeds of about $55,392. Acquisition details show the shares were originally purchased in 2013-2014 from Deutsche Bank for cash. No adverse undisclosed information is attested by the filer, and the signature section affirms compliance with Rule 144 and Rule 10b5-1 provisions.

Given the small size of the transaction relative to MetLife’s market capitalization and float, the notice is largely administrative and unlikely to affect the company’s financial condition or share price.

MetLife, Inc. (MET) ha depositato un modulo Form 144 annunciando una proposta di vendita di 547 azioni ordinarie tramite Barclays Capital il 20 giugno 2025. Il valore di mercato complessivo della vendita proposta è di 42.966,85 $, rispetto alle 671.297.826 azioni attualmente in circolazione, rappresentando circa lo 0,00008% delle azioni in circolazione.

La documentazione elenca vendite precedenti negli ultimi tre mesi da vari conti collegati a MetLife per un totale di 686 azioni e proventi lordi di circa 55.392 $. I dettagli sull’acquisizione indicano che le azioni sono state originariamente acquistate nel 2013-2014 da Deutsche Bank in contanti. Il firmatario attesta l’assenza di informazioni negative non divulgate e la sezione firme conferma il rispetto delle disposizioni della Regola 144 e della Regola 10b5-1.

Considerata la dimensione ridotta della transazione rispetto alla capitalizzazione di mercato e al flottante di MetLife, la comunicazione ha carattere principalmente amministrativo ed è improbabile che influenzi la situazione finanziaria o il prezzo delle azioni della società.

MetLife, Inc. (MET) presentó un Formulario 144 anunciando una propuesta de venta de 547 acciones ordinarias a través de Barclays Capital el 20 de junio de 2025. El valor de mercado total de la venta propuesta es de 42,966.85 $, en comparación con las 671,297,826 acciones actualmente en circulación, lo que representa aproximadamente el 0.00008 % de las acciones en circulación.

El documento enumera ventas previas en los últimos tres meses por diversas cuentas relacionadas con MetLife que suman 686 acciones y unos ingresos brutos de alrededor de 55,392 $. Los detalles de adquisición muestran que las acciones fueron originalmente compradas en 2013-2014 a Deutsche Bank en efectivo. El declarante certifica que no hay información adversa no divulgada y la sección de firmas confirma el cumplimiento de las reglas 144 y 10b5-1.

Dado el tamaño reducido de la transacción en relación con la capitalización de mercado y el flotante de MetLife, el aviso es principalmente administrativo y es poco probable que afecte la condición financiera o el precio de las acciones de la empresa.

MetLife, Inc. (MET)는 Form 144를 제출했습니다 2025년 6월 20일 Barclays Capital을 통해 547주의 보통주 매각을 제안한다고 발표했습니다. 제안된 매각의 총 시장 가치는 42,966.85달러이며, 현재 발행 주식 수인 671,297,826주와 비교할 때 약 0.00008%에 해당합니다.

신고서에는 최근 3개월간 MetLife 관련 계정에서 총 686주를 매각하여 약 55,392달러의 총수익을 올린 내역이 나와 있습니다. 취득 내역에 따르면 해당 주식은 2013-2014년에 Deutsche Bank로부터 현금으로 구매된 것입니다. 신고자는 공개되지 않은 불리한 정보가 없음을 확인했으며, 서명란에서는 Rule 144 및 Rule 10b5-1 준수를 확인했습니다.

MetLife의 시가총액과 유통 주식 수에 비해 거래 규모가 매우 작기 때문에 이번 공지는 주로 행정적 성격이며 회사의 재무 상태나 주가에 영향을 미칠 가능성은 낮습니다.

MetLife, Inc. (MET) a déposé un formulaire 144 annonçant une vente proposée de 547 actions ordinaires via Barclays Capital le 20 juin 2025. La valeur marchande totale de la vente proposée est de 42 966,85 $, comparée aux 671 297 826 actions actuellement en circulation, ce qui représente environ 0,00008 % des actions en circulation.

Le dépôt liste des ventes antérieures au cours des trois derniers mois par divers comptes liés à MetLife totalisant 686 actions et des recettes brutes d’environ 55 392 $. Les détails d’acquisition indiquent que les actions ont été initialement achetées en 2013-2014 auprès de Deutsche Bank en espèces. Le déclarant atteste qu’aucune information défavorable non divulguée n’existe, et la section de signature confirme la conformité avec les règles 144 et 10b5-1.

Compte tenu de la petite taille de la transaction par rapport à la capitalisation boursière et au flottant de MetLife, cet avis est principalement administratif et est peu susceptible d’affecter la situation financière ou le cours de l’action de la société.

MetLife, Inc. (MET) hat ein Formular 144 eingereicht, in dem ein geplanter Verkauf von 547 Stammaktien über Barclays Capital am 20. Juni 2025 angekündigt wird. Der Gesamtmarktwert des geplanten Verkaufs beträgt 42.966,85 $, verglichen mit 671.297.826 ausstehenden Aktien, was etwa 0,00008 % der ausstehenden Aktien entspricht.

Die Einreichung listet frühere Verkäufe in den letzten drei Monaten von verschiedenen MetLife-bezogenen Konten mit insgesamt 686 Aktien und Bruttoerlösen von etwa 55.392 $ auf. Die Erwerbsdetails zeigen, dass die Aktien ursprünglich 2013-2014 von der Deutschen Bank gegen Barzahlung erworben wurden. Der Einreicher bestätigt das Fehlen von nicht offengelegten nachteiligen Informationen, und der Unterschriftsbereich bestätigt die Einhaltung der Regel 144 und Regel 10b5-1.

Angesichts der geringen Größe der Transaktion im Verhältnis zur Marktkapitalisierung und zum Streubesitz von MetLife ist die Mitteilung hauptsächlich administrativer Natur und wird wahrscheinlich weder die finanzielle Lage noch den Aktienkurs des Unternehmens beeinflussen.

Positive
  • Transparency maintained: Management or plan trustees disclosed the planned sale in accordance with Rule 144 requirements.
  • Negligible dilution risk: 547 shares represent only 0.00008 % of outstanding shares.
Negative
  • Insider/affiliate selling, even if small, can be interpreted as a lack of incremental insider buying interest.

Insights

TL;DR: Tiny Rule 144 sale (547 MET shares, $43K) is immaterial to float or valuation.

The filing discloses an intended disposition of 547 common shares—miniscule versus the 671 million shares outstanding. Even aggregated with the past-quarter sales (686 shares), the total liquidations equal roughly $0.1 million, far below any materiality threshold for a large-cap insurer like MetLife. Such routine plan-level or employee transactions rarely signal strategic shifts or deteriorating fundamentals. Investors may note continued transparency, but the event should be classified as non-impactful to earnings, liquidity, or governance.

MetLife, Inc. (MET) ha depositato un modulo Form 144 annunciando una proposta di vendita di 547 azioni ordinarie tramite Barclays Capital il 20 giugno 2025. Il valore di mercato complessivo della vendita proposta è di 42.966,85 $, rispetto alle 671.297.826 azioni attualmente in circolazione, rappresentando circa lo 0,00008% delle azioni in circolazione.

La documentazione elenca vendite precedenti negli ultimi tre mesi da vari conti collegati a MetLife per un totale di 686 azioni e proventi lordi di circa 55.392 $. I dettagli sull’acquisizione indicano che le azioni sono state originariamente acquistate nel 2013-2014 da Deutsche Bank in contanti. Il firmatario attesta l’assenza di informazioni negative non divulgate e la sezione firme conferma il rispetto delle disposizioni della Regola 144 e della Regola 10b5-1.

Considerata la dimensione ridotta della transazione rispetto alla capitalizzazione di mercato e al flottante di MetLife, la comunicazione ha carattere principalmente amministrativo ed è improbabile che influenzi la situazione finanziaria o il prezzo delle azioni della società.

MetLife, Inc. (MET) presentó un Formulario 144 anunciando una propuesta de venta de 547 acciones ordinarias a través de Barclays Capital el 20 de junio de 2025. El valor de mercado total de la venta propuesta es de 42,966.85 $, en comparación con las 671,297,826 acciones actualmente en circulación, lo que representa aproximadamente el 0.00008 % de las acciones en circulación.

El documento enumera ventas previas en los últimos tres meses por diversas cuentas relacionadas con MetLife que suman 686 acciones y unos ingresos brutos de alrededor de 55,392 $. Los detalles de adquisición muestran que las acciones fueron originalmente compradas en 2013-2014 a Deutsche Bank en efectivo. El declarante certifica que no hay información adversa no divulgada y la sección de firmas confirma el cumplimiento de las reglas 144 y 10b5-1.

Dado el tamaño reducido de la transacción en relación con la capitalización de mercado y el flotante de MetLife, el aviso es principalmente administrativo y es poco probable que afecte la condición financiera o el precio de las acciones de la empresa.

MetLife, Inc. (MET)는 Form 144를 제출했습니다 2025년 6월 20일 Barclays Capital을 통해 547주의 보통주 매각을 제안한다고 발표했습니다. 제안된 매각의 총 시장 가치는 42,966.85달러이며, 현재 발행 주식 수인 671,297,826주와 비교할 때 약 0.00008%에 해당합니다.

신고서에는 최근 3개월간 MetLife 관련 계정에서 총 686주를 매각하여 약 55,392달러의 총수익을 올린 내역이 나와 있습니다. 취득 내역에 따르면 해당 주식은 2013-2014년에 Deutsche Bank로부터 현금으로 구매된 것입니다. 신고자는 공개되지 않은 불리한 정보가 없음을 확인했으며, 서명란에서는 Rule 144 및 Rule 10b5-1 준수를 확인했습니다.

MetLife의 시가총액과 유통 주식 수에 비해 거래 규모가 매우 작기 때문에 이번 공지는 주로 행정적 성격이며 회사의 재무 상태나 주가에 영향을 미칠 가능성은 낮습니다.

MetLife, Inc. (MET) a déposé un formulaire 144 annonçant une vente proposée de 547 actions ordinaires via Barclays Capital le 20 juin 2025. La valeur marchande totale de la vente proposée est de 42 966,85 $, comparée aux 671 297 826 actions actuellement en circulation, ce qui représente environ 0,00008 % des actions en circulation.

Le dépôt liste des ventes antérieures au cours des trois derniers mois par divers comptes liés à MetLife totalisant 686 actions et des recettes brutes d’environ 55 392 $. Les détails d’acquisition indiquent que les actions ont été initialement achetées en 2013-2014 auprès de Deutsche Bank en espèces. Le déclarant atteste qu’aucune information défavorable non divulguée n’existe, et la section de signature confirme la conformité avec les règles 144 et 10b5-1.

Compte tenu de la petite taille de la transaction par rapport à la capitalisation boursière et au flottant de MetLife, cet avis est principalement administratif et est peu susceptible d’affecter la situation financière ou le cours de l’action de la société.

MetLife, Inc. (MET) hat ein Formular 144 eingereicht, in dem ein geplanter Verkauf von 547 Stammaktien über Barclays Capital am 20. Juni 2025 angekündigt wird. Der Gesamtmarktwert des geplanten Verkaufs beträgt 42.966,85 $, verglichen mit 671.297.826 ausstehenden Aktien, was etwa 0,00008 % der ausstehenden Aktien entspricht.

Die Einreichung listet frühere Verkäufe in den letzten drei Monaten von verschiedenen MetLife-bezogenen Konten mit insgesamt 686 Aktien und Bruttoerlösen von etwa 55.392 $ auf. Die Erwerbsdetails zeigen, dass die Aktien ursprünglich 2013-2014 von der Deutschen Bank gegen Barzahlung erworben wurden. Der Einreicher bestätigt das Fehlen von nicht offengelegten nachteiligen Informationen, und der Unterschriftsbereich bestätigt die Einhaltung der Regel 144 und Regel 10b5-1.

Angesichts der geringen Größe der Transaktion im Verhältnis zur Marktkapitalisierung und zum Streubesitz von MetLife ist die Mitteilung hauptsächlich administrativer Natur und wird wahrscheinlich weder die finanzielle Lage noch den Aktienkurs des Unternehmens beeinflussen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Slootman Frank

(Last) (First) (Middle)
C/O SNOWFLAKE INC.
106 EAST BABCOCK STREET, SUITE 3A

(Street)
BOZEMAN MT 59715

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Snowflake Inc. [ SNOW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/26/2025 M(1) 424,852 A $8.88 590,359(2) D
Class A Common Stock 06/26/2025 S(1) 71,178 D $216.298(3) 519,181(2) D
Class A Common Stock 06/26/2025 S(1) 85,322 D $217.053(4) 433,859(2) D
Class A Common Stock 06/26/2025 S(1) 20,799 D $218.119(5) 413,060(2) D
Class A Common Stock 06/26/2025 S(1) 20,075 D $219.137(6) 392,985(2) D
Class A Common Stock 06/26/2025 S(1) 41,872 D $220.331(7) 351,113(2) D
Class A Common Stock 06/26/2025 S(1) 99,327 D $221.199(8) 251,786(2) D
Class A Common Stock 06/26/2025 S(1) 86,138 D $221.862(9) 165,648(2) D
Class A Common Stock 06/26/2025 S(1) 141 D $222.79 165,507(2) D
Class A Common Stock 06/27/2025 M(1) 306,502 A $8.88 472,009(2) D
Class A Common Stock 06/27/2025 S(1) 13,787 D $220.305(10) 458,222(2) D
Class A Common Stock 06/27/2025 S(1) 38,548 D $221.398(11) 419,674(2) D
Class A Common Stock 06/27/2025 S(1) 178,845 D $222.462(12) 240,829(2) D
Class A Common Stock 06/27/2025 S(1) 65,016 D $223.285(13) 175,813(2) D
Class A Common Stock 06/27/2025 S(1) 10,306 D $224.15(14) 165,507(2) D
Class A Common Stock 6,384 I LLC(15)
Class A Common Stock 83,014 I Foundation(16)
Class A Common Stock 335,146 I Trust(17)
Class A Common Stock 250,030 I Trust(18)
Class A Common Stock 16,300 I Trust(19)
Class A Common Stock 91,058 I Trust(20)
Class A Common Stock 91,058 I Trust(21)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $8.88 06/26/2025 M(1) 424,852 (22) 05/28/2029 Class A Common Stock 424,852 $0 9,670,512 D
Stock Option (Right to Buy) $8.88 06/27/2025 M(1) 306,502 (22) 05/28/2029 Class A Common Stock 306,502 $0 9,364,010 D
Explanation of Responses:
1. The exercises and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 26, 2025.
2. Includes shares to be issued in connection with the vesting of one or more restricted stock units.
3. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $215.655 to $216.650, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
4. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $216.660 to $217.650, inclusive.
5. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $217.660 to $218.645, inclusive.
6. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $218.660 to $219.640, inclusive.
7. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $219.680 to $220.675, inclusive.
8. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $220.680 to $221.675, inclusive.
9. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $221.680 to $222.310, inclusive.
10. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $219.910 to $220.900, inclusive.
11. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $220.910 to $221.900, inclusive.
12. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $221.910 to $222.900, inclusive.
13. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $222.910 to $223.900, inclusive.
14. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $223.910 to $224.370, inclusive.
15. The shares are held by Invisible Hand Ventures, LLC, of which the Reporting Person is the manager and has sole voting and dispositive power.
16. The shares are held by the Slootman Family Foundation dated 11/24/2010 for which the Reporting Person is deemed to have voting and investment power over the shares held by the Slootman Family Foundation, but has no personal pecuniary interest in these shares.
17. The shares are held by the Slootman Living Trust dated 9/8/1999 for which the Reporting Person is a trustee.
18. The shares are held by the Slootman 2023 Grantor Retained Annuity Trust dated 9/25/23 for which the Reporting Person is a trustee.
19. The shares are held by the Slootman Grandchildren's Trust dated 7/28/2022 for which the Reporting Person is a trustee.
20. The shares are held by the B. Slootman 2024 Grantor Retained Annuity Trust dated 12/3/2024 for which the Reporting Person's spouse is the trustee.
21. The shares are held by the F. Slootman 2024 Grantor Retained Annuity Trust dated 12/3/2024 for which the Reporting Person is the trustee.
22. The stock option is fully vested.
Remarks:
/s/ Marie Reider, Attorney-in-Fact 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MetLife (MET) shares are being sold under this Form 144 filing?

547 common shares are slated for sale.

What is the estimated market value of the proposed MET share sale?

Approximately $42,966.85 based on the filing’s figures.

When is the expected sale date for the MET shares?

The filing lists an approximate sale date of 20 June 2025.

How does the sale size compare to MetLife’s shares outstanding?

It equals about 0.00008 % of the 671,297,826 shares outstanding.

Have there been recent sales by the same seller in the last 3 months?

Yes, a total of 686 shares were sold between March and June 2025 for roughly $55,392 in gross proceeds.
Snowflake Inc

NYSE:SNOW

SNOW Rankings

SNOW Latest News

SNOW Latest SEC Filings

SNOW Stock Data

71.31B
319.54M
4.85%
65.8%
3.12%
Software - Application
Services-prepackaged Software
Link
United States
BOZEMAN